Alnylam Pharmaceuticals Inc. (ALNY)
Alnylam (ALNY) Amvuttra & Givlaari Fuel Revenues Amid Competition
Alnylam's (ALNY) Amvuttra and Givlaari sales continue to boost revenues. However, its reliance on collaboration partners and stiff competition remain concerns.
The 3 Best Gene Editing Stocks to Buy in August 2024
Investing guru Cathie Wood sees precision therapeutics as a massive growth market. She forecasts sales in the category can grow by a compound annual growth rate (CAGR) of 30% through 2030.
Alnylam (ALNY) Up as Q2 Earnings Beat on Collaboration Revenues
Alnylam (ALNY) gains 13% on upbeat second-quarter results, beating both earnings and revenue estimates, primarily driven by higher collaboration revenues from Regeneron and strong Amvuttra sales.
Alnylam Pharmaceuticals, Inc. (ALNY) Q2 2024 Earnings Call Transcript
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY ) Q2 2024 Earnings Conference Call August 1, 2024 8:00 AM ET Company Participants Christine Lindenboom - SVP, IR and Corporate Communications Yvonne Greenstreet - CEO Tolga Tanguler - CCO Pushkal Garg - CMO Jeff Poulton - CFO Conference Call Participants Tazeen Ahmad - Bank of America Maury Raycroft - Jefferies Julian Pino - Stifel Kostas Biliouris - BMO Capital Markets Jessica Fye - JPMorgan David Lebowitz - Citi Gena Wang - Barclays Ritu Baral - TD Cowen Mike Ulz - Morgan Stanley William Pickering - Bernstein Myles Minter - William Blair Luca Issi - RBC Capital Operator Good day and thank you for standing by. Welcome to the Alnylam Pharmaceuticals Second Quarter 2024 Conference Call.
Alnylam (ALNY) Reports Q2 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Alnylam (ALNY) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Alnylam Pharmaceuticals (ALNY) Q2 Earnings and Revenues Beat Estimates
Alnylam Pharmaceuticals (ALNY) came out with quarterly earnings of $0.56 per share, beating the Zacks Consensus Estimate of a loss of $0.74 per share. This compares to loss of $2.21 per share a year ago.
Seeking Clues to Alnylam (ALNY) Q2 Earnings? A Peek Into Wall Street Projections for Key Metrics
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Alnylam (ALNY), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2024.
Alnylam Pharmaceuticals (ALNY) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Alnylam (ALNY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Alnylam Stock Is a Blockbuster Biopharma In the Making
Biopharmaceutical stock Alnylam Pharmaceuticals (NASDAQ: ALNY ) is riding a tsunami of hope that a treatment for a rare heart condition receives Food & Drug Administration approval. Although it has several drugs already on the market, the biopharma is not yet profitable.
35% Surge Just the Beginning? Alnylam's Stock Poised for Massive Gains on Heart Drug Success.
Could Alnylam Pharmaceuticals (NASDAQ: ALNY ) become a household name in 2024? At the very least, the company should be well known in the medical community.
7 Cheap Biotech Stocks With Major Upside Potential
Intuitively, the case for biotechnology-related investments comes across rather obviously: the concept of healthcare should be a permanent one. And because of this permanence, the expected market value of the ecosystem should be massive.
What's Next For Alnylam Stock After A 60% Rise In A Week?
Alnylam Pharmaceuticals stock (NASDAQ: ALNY), a pharmaceutical company focused on RNA interference therapeutics for genetically defined diseases, has seen a significant rise of 60% in a week. This can be attributed to positive data from a late-stage clinical trial for its cardiovascular drug, Amvuttra.
